IGF-1 LR3: Side Effects & Safety
Part of the IGF-1 LR3 Complete Guide
Research Peptides
We may earn a commission if you purchase through this link, at no extra cost to you.
Overall Safety Profile
IGF-1 LR3 carries significant safety considerations due to its potency and non-specific growth-promoting effects. It is not FDA-approved for any human use and should be treated with particular caution among research peptides.
Reported Side Effects
- Hypoglycemia: Potentially serious — IGF-1 LR3 lowers blood glucose significantly. Always have glucose available
- Joint pain and swelling: Related to growth-promoting effects
- Water retention: Can be significant
- Jaw and extremity growth: With prolonged use (acromegaly-like effects)
- Injection site reactions
Critical Safety Concerns
- Cancer risk: IGF-1 signaling promotes cell proliferation — elevated IGF-1 is epidemiologically associated with increased cancer risk
- Organ growth: Long-term IGF-1R activation can cause organomegaly (enlargement of internal organs)
- No human clinical trials: Safety and efficacy in humans have not been formally evaluated
Contraindications
- Active cancer or history of cancer
- Diabetes or hypoglycemia-prone conditions
- Acromegaly or gigantism
- Pregnancy and breastfeeding